NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · AUGX · USD
Stock price, earnings
Quote as of Oct 1, 2024, 07:57 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Augmedix, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Augmedix, Inc. is a U.S.-based company specializing in remote medical documentation and offering live support to clinical professionals. Its comprehensive platform, comprising Augmedix Live and Augmedix Notes, streamlines the entire documentation process for patient encounters. This includes preparatory tasks like pre-charting and digitizing historical patient data prior to appointments. During the consultation, it generates essential medical notes, flags care gaps, provides HCC reminders, and produces after-visit summaries. Post-visit, the system facilitates crucial administrative duties such as medical coding, processing orders, and managing referrals. Clinicians can readily access these applications via mobile devices, including smartphones or specialized wearables like Google Glass. The company's clientele primarily consists of various health systems and distinct specialty groups. Founded in 2013, Augmedix maintains its corporate headquarters in San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | May 12, 2023 | -$0.14+6.67% vs estimate | $9.63M+2.51% vs estimate |
|---|
| Q4 2022 | Mar 27, 2023 | -$0.150.0% vs estimate | $8.75M-23.37% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$26.24$0.00 (0.0%)
TruBridge, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$3.02-$0.07 (-2.27%)
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$1.01+$1.01 (+100.0%)
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
